{"id":"quetiapine-fumarate-vs-risperidone","safety":{"commonSideEffects":[{"rate":"15-25%","effect":"Sedation/somnolence"},{"rate":"10-20%","effect":"Weight gain"},{"rate":"10-15%","effect":"Dizziness"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-15%","effect":"Extrapyramidal symptoms"},{"rate":"5-10%","effect":"Akathisia"},{"rate":"5-15%","effect":"Hyperglycemia/metabolic effects"}]},"_chembl":{"chemblId":"CHEMBL3188993","moleculeType":"Small molecule","molecularWeight":"883.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are second-generation antipsychotics used to treat psychotic disorders and bipolar disorder. Quetiapine has a faster dissociation from D2 receptors and lower extrapyramidal side effect risk, while risperidone has greater potency at D2 receptors and may be more effective for certain psychotic symptoms. They differ in pharmacokinetics, side effect profiles, and clinical efficacy across different patient populations.","oneSentence":"Quetiapine fumarate is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain, while risperidone is a similar atypical antipsychotic with higher D2 receptor affinity and additional alpha-adrenergic blocking activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:27.330Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT00161018","phase":"PHASE3","title":"New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2003-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT01739127","phase":"","title":"Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2012-11","conditions":"Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X","enrollment":83},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT00237861","phase":"PHASE4","title":"Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia","status":"COMPLETED","sponsor":"Yale University","startDate":"","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00034905","phase":"PHASE4","title":"A Comparison of Seroquel vs. Risperidone in Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-07","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00061802","phase":"PHASE4","title":"Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"quetiapine fumarate vs risperidone","genericName":"quetiapine fumarate vs risperidone","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quetiapine fumarate is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain, while risperidone is a similar atypical antipsychotic with higher D2 receptor affinity and additional alpha-adrenergic blocking activity. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}